<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
x

Beyond Syngeneics – Novel Tools for Addressing Human Specificity in Immuno-Oncology

Checkpoint inhibitors such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 have revolutionized immunotherapy, and are now approved for a range of cancer types.